Apogee Therapeutics Inc. has selected a development candidate for its APG-990 program, a subcutaneous half-life extended monoclonal antibody targeting OX40L, initially being developed for atopic dermatitis.
Vyne Therapeutics Inc. has received IND clearance from the FDA allowing it to initiate a first-in-human phase Ia study of VYN-202, an oral small-molecule BD2-selective BET inhibitor for autoimmune diseases.
Scientists from the Centre for Genomic Regulation and collaborators have developed a new approach to limiting the amount of collagen produced by hyperactive fibroblasts, which could lead to effective treatments for fibrotic diseases and scarring.
Eli Lilly & Co. has synthesized glucocorticoid receptor (GR) agonists reported to be useful for the treatment of atopic dermatitis and rheumatoid arthritis.
Derm-Biome Pharmaceuticals Inc. has developed a topical anticancer treatment for patients with or at high risk of developing multiple actinic keratoses.
Sitryx Therapeutics Ltd. has nominated SYX-5219 as the first candidate from its proprietary pipeline to progress to regulatory nonclinical studies to support a clinical trial authorization (CTA). SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis.
RSS
